

## Original Paper

**Cite this article:** Manges AR, Thuras P, Porter S, Johnson JR (2019). Self-reported risk factors for having *Escherichia coli* sequence type 131 or its H30 subclone among US Veterans with a clinical *E. coli* isolate. *Epidemiology and Infection* **147**, e55, 1–7. <https://doi.org/10.1017/S0950268818003114>

Received: 20 April 2018

Revised: 19 September 2018

Accepted: 24 October 2018

**Key words:**

Antimicrobial resistance; epidemiology; *Escherichia coli*; extraintestinal pathogenic *E. coli*; multidrug resistance; ST131

**Author for correspondence:**

James R. Johnson, E-mail: [johns007@umn.edu](mailto:johns007@umn.edu)

# Self-reported risk factors for having *Escherichia coli* sequence type 131 or its H30 subclone among US Veterans with a clinical *E. coli* isolate

Amee R. Manges<sup>1</sup>, Paul Thuras<sup>2,3</sup>, Stephen Porter<sup>2</sup> and James R. Johnson<sup>2,4</sup>

<sup>1</sup>School of Population and Public Health, University of British Columbia, Vancouver, Canada; <sup>2</sup>Minneapolis Veterans Health Care System, Minneapolis, Minnesota, USA; <sup>3</sup>Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA and <sup>4</sup>Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA

**Abstract**

Among 469 US military veterans with an *Escherichia coli* clinical isolate (2012–2013), we explored healthcare and non-healthcare risk factors for having *E. coli* sequence type 131 and its H30 subclone (ST131-H30). Overall, 66 (14%) isolates were ST131; 51 (77%) of these were ST131-H30. After adjustment for healthcare-associated factors, ST131 remained positively associated with medical lines and nursing home residence. After adjustment for environmental factors, ST131 remained associated with wild animal contact (positive), meat consumption (negative) and pet cat exposure (negative). Thus, ST131 was associated predominantly with healthcare-associated exposures, while non-ST131 *E. coli* were associated with some environmental exposures.

*Escherichia coli* sequence type (ST131) is a recently emerged, multidrug-resistant lineage of *E. coli* that has expanded tremendously over the past two decades to become the main cause of extraintestinal *E. coli* infections in humans [1, 2]. Within ST131, the H30R subclone predominates and accounts for almost all fluoroquinolone-resistant isolates [3]. Within ST131-H30R, the H30Rx subclone is additionally associated with the CTX-M-15 extended-spectrum  $\beta$ -lactamase, conferring resistance to extended-spectrum cephalosporins. This broad and often unanticipated resistance leads to adverse clinical outcomes [4].

Preventive interventions against these threatening new pathogens are sorely needed, but few modifiable risk factors have been discovered. Many studies have identified clinical and healthcare-associated risk factors for ST131 infection, usually based on data obtained by medical record review. Here, among US military veterans, we sought novel risk factors for having an ST131-H30 clinical isolate by investigating self-reported clinical factors, demographic characteristics and environmental exposures.

**Methods****Study subjects and *E. coli* isolates**

Consecutive clinical *E. coli* isolates were collected from the Minneapolis VA Medical Center (MVAMC; Minneapolis, MN) clinical microbiology laboratory from May 2012 to December 2013. The source patients were sent an invitation to participate in the study and a paper-based questionnaire, which requested demographic and exposure information. Participants returned completed questionnaires by mail. Telephone follow-up was used to facilitate survey completion for some subjects, without knowledge of laboratory testing results. The MVAMC institutional review board (4181-A) approved the study.

**Clinical microbiology**

The MVAMC clinical laboratory identified the *E. coli* isolates using standard methods and determined susceptibility to 12 antimicrobial agents and extended-spectrum beta-lactamase (ESBL) production using the BD Phoenix Automated Microbiology System (Becton Dickinson and Company, Sparks, MD, USA) per manufacturer guidelines, utilising NMIC/ID-123 panels. Minimum inhibitory concentration (MIC) results were interpreted according to Clinical Laboratory and Standards Institute criteria [5].

**Molecular typing**

Isolates were characterised using established polymerase chain reaction (PCR)-based assays for membership in the ST131-H30 clonal subset or its ST131-H30Rx sublineage [3] and O type

**Table 1.** Characteristics of 469 veterans with an *Escherichia coli* clinical isolate, stratified by ST131 status

| Characteristic                     | Prevalence of characteristic, no (column %) |                |                     | P-value* |
|------------------------------------|---|----------------|---------------------|----------|
|                                    | Total (n = 469)                             | ST131 (n = 66) | Non-ST131 (n = 403) |          |
| Sex (male)                         | 383 (82)                                    | 57 (86)        | 326 (81)            | 0.32     |
| Age                                |   |                |                     | 0.42     |
| ≤35 years                          | 19 (4)                                      | 2 (3)          | 17 (4)              |          |
| 36–45                              | 8 (2)                                       | 0 (0)          | 8 (2)               |          |
| 46–55                              | 65 (14)                                     | 5 (8)          | 60 (15)             |          |
| 56–65                              | 138 (30)                                    | 18 (27)        | 120 (30)            |          |
| 66–75                              | 108 (23)                                    | 20 (30)        | 88 (22)             |          |
| 76–85                              | 92 (20)                                     | 15 (23)        | 77 (19)             |          |
| ≥86                                | 39 (8)                                      | 6 (9)          | 33 (8)              |          |
| Income                             |   |                |                     | 0.43     |
| <\$25 000                          | 190 (41)                                    | 29 (44)        | 161 (41)            |          |
| \$25 000–\$50 000                  | 164 (35)                                    | 23 (35)        | 141 (36)            |          |
| \$50 000–\$75 000                  | 52 (11)                                     | 7 (11)         | 45 (11)             |          |
| \$75 000–\$100 000                 | 29 (6)                                      | 2 (3)          | 27 (7)              |          |
| >\$100 000                         | 8 (2)                                       | 0 (0)          | 8 (2)               |          |
| Unknown                            | 18 (4)                                      | 5 (8)          | 13 (3)              |          |
| Urban/Rural                        |   |                |                     | 0.34     |
| Large city (>20 000)               | 259 (55)                                    | 40 (61)        | 219 (54)            |          |
| Medium to small city (5000–20 000) | 81 (17)                                     | 7 (11)         | 74 (18)             |          |
| Village (<5000)                    | 83 (18)                                     | 15 (23)        | 68 (17)             |          |
| Rural                              | 44 (9)                                      | 4 (6)          | 40 (10)             |          |
| Other                              | 1 (<1)                                      | 0 (0)          | 1 (1)               |          |
| Dwelling                           |   |                |                     | 0.5      |
| Apartment                          | 106 (23)                                    | 15 (23)        | 91 (23)             |          |
| Private home                       | 326 (70)                                    | 48 (74)        | 278 (70)            |          |
| Institution                        | 11 (2)                                      | 0 (0)          | 11 (3)              |          |
| Other                              | 22 (5)                                      | 2 (3)          | 20 (5)              |          |
| Households with children           | 44 (9)                                      | 4 (6)          | 62 (13)             | 0.31     |
| Health status                      |   |                |                     | 0.82     |
| Excellent                          | 27 (6)                                      | 4 (6)          | 23 (6)              |          |
| Good                               | 167 (36)                                    | 26 (39)        | 141 (35)            |          |
| Average                            | 116 (25)                                    | 13 (20)        | 103 (26)            |          |
| Fair                               | 97 (21)                                     | 13 (20)        | 84 (21)             |          |
| Poor                               | 59 (13)                                     | 10 (15)        | 49 (12)             |          |
| Co-morbidities <sup>a</sup>        |   |                |                     |          |
| Diabetes                           | 142 (30)                                    | 21 (32)        | 121 (30)            | 0.77     |
| Chronic lung disease               | 85 (18)                                     | 14 (21)        | 71 (18)             |          |
| Chronic heart disease              | 114 (24)                                    | 7 (11)         | 107 (27)            |          |
| Renal disease                      | 48 (10)                                     | 10 (15)        | 38 (9)              |          |
| Immunodeficiency                   | 28 (6)                                      | 2 (3)          | 26 (6)              |          |
| Chronic liver disease              | 20 (4)                                      | 1 (2)          | 19 (5)              |          |

(Continued)

**Table 1.** (Continued.)

| Characteristic               | Prevalence of characteristic, no (column %) |                |                     | P-value* |
|------------------------------|---|----------------|---------------------|----------|
|                              | Total (n = 469)                             | ST131 (n = 66) | Non-ST131 (n = 403) |          |
| Stroke or neurologic disease | 51 (11)                                     | 9 (14)         | 42 (10)             |          |
| Cancer                       | 140 (30)                                    | 23 (35)        | 117 (29)            |          |

All variables included results for between 462 and 469 subjects.

\*Subjects could report more than one co-morbidity.

\*P-value corresponds to an overall  $\chi^2$  test.

(O16 and O25b only) [6]. PCR was done using boiled lysates for template DNA, with appropriate positive and negative control strains.

### Statistical analysis

Comparisons of proportions were made using  $\chi^2$  and Fisher exact tests. Exposures associated significantly with either ST131 or H30 were included in multiple logistic regression models, which were performed separately for clinical and environmental risk factors.

## Results

### Clinical and epidemiological data

Over the 20-month study period (May 2012–December 2013), the MVAMC clinical microbiology laboratory recovered *E. coli* from 925 unique veterans, of whom 469 (51%) opted to complete the study survey. Most subjects were male (82%); half were 66 years or older (Table 1). Most were seen in the outpatient setting (384; 83%); the rest (79; 17%) had been hospitalised for 48 h or more. The most common specimen types were urine (366; 78%), wound swab (52; 11%) and blood (15; 3%).

### Antimicrobial susceptibility

Ampicillin was the most commonly detected resistance phenotype (187; 40%), followed by ciprofloxacin (84; 18%), ampicillin-sulbactam (80; 17%) and trimethoprim-sulfamethoxazole (77; 16%). No isolate was carbapenem-resistant. Eighty-five isolates (18%) were resistant to  $\geq 3$  antimicrobial agents and 21 (4%) to  $\geq 5$  antimicrobial agents.

### Prevalence of ST131 and its subsets

ST131 accounted for 66 (14%) of the 469 study isolates. Of the 66 ST131 isolates, 51 (77%) were ST131-H30, of which 43 (84%) represented the H30R1 subclone and 8 (12%) the ST131-H30Rx subclone. Subjects with ST131 vs. non-ST131 isolates did not differ significantly on demographic characteristics, including age, dwelling type, health status, or comorbidities (Table 1).

Among the 66 ST131 isolates, all 51 H30 isolates, but only 2/15 (13%) non-H30 isolates, were fluoroquinolone-resistant ( $P$ -value < 0.001). Sixty-three (95%) of the ST131 isolates were typed as O25b; 51 (88%) of these were H30.

### Clinical factors and ST131 and ST131-H30

Overall, ST131 was significantly associated with exposure to medical lines (within the past month ( $P$ -value = 0.005) or 6 months ( $P$ -value < 0.001)), hospitalisation ( $P$ -value = 0.004),

nursing home residence ( $P$ -value = 0.001), surgery ( $P$ -value = 0.01) and antimicrobial exposure in the past 6 months ( $P$ -value = 0.008) (Table 2). ST131 also was over-represented among isolates from non-blood, wound, or urine specimens ( $P$ -value = 0.01) (Table 2).

By contrast, among ciprofloxacin-resistant isolates, clinical risk factors did not differ significantly between ST131 ( $n$  = 53) and non-ST131 ( $n$  = 31) isolates (Table 2). Similarly, among ST131 isolates, the only clinical risk factor that differed H30 from non-H30 isolates was wound source, which was weakly associated with non-H30 isolates (Table 2).

Multiple logistic regression was used to identify clinical variables independently associated with *E. coli* ST131. Overall, after adjustment for variables significantly associated with ST131 in the univariable analyses, only medical line used in the past 6 months (adjusted OR 2.14, 95% CI 1.23–3.74) and nursing home residence (adjusted OR 2.92, 95% CI 1.3–6.76) remained significantly associated with ST131. In univariable analyses, no clinical variable was associated with ST131 status among ciprofloxacin-resistant isolates and only one variable (wound source) was associated with H30 status among ST131 isolates (Table 2) and for these subsets, multiple logistic regression was not performed.

### Environmental factors and ST131 and ST131-H30

Overall, ST131 was associated positively with touching wild animals ( $P$ -value = 0.03) and negatively with meat consumption ( $P$ -value = 0.01), cat contact ( $P$ -value = 0.02) and touching animal feces ( $P$ -value = 0.03) (Table 3). Among subjects with a ciprofloxacin-resistant isolate ( $n$  = 84), ST131 was associated positively with farm animal contact ( $P$ -value = 0.05) and touching wild animals ( $P$ -value = 0.02) and negatively with using city water ( $P$ -value = 0.05) and cat contact ( $P$ -value = 0.01). Among subjects with an ST131 isolate ( $n$  = 66), H30 was associated negatively with past-month out-of-state travel ( $P$ -value = 0.05).

Multiple logistic regression was used to identify environmental variables independently associated with carriage of *E. coli* ST131. After adjustment for variables associated with ST131 in the univariable analyses, contact with wild animals (adjusted OR 2.49, 95% CI 1.16–5.33) remained positively associated and meat consumption (adjusted OR 0.48, 95% CI 0.28–0.82) and pet cat exposure (adjusted OR 0.37, 95% CI 0.17–0.77) remained negatively associated, with ST131. With wild animal contact in the model, contact with animal feces was no longer associated with ST131 (*data not shown*). Multiple logistic regression was not performed for subjects with ciprofloxacin-resistant *E. coli*, all of whom reported contact with wild or companion animals, or for subjects with ST131 since within this subset only one H30-associated variable (out-of-state travel) was identified.

**Table 2.** Clinical factors and *E. coli* ST131 carriage, by ciprofloxacin resistance and ST131 H30 sub-group

| Clinical factor    | Time frame or sample type | Total | All isolates ( <i>n</i> = 469) |                             |                  | Ciprofloxacin-resistant ( <i>n</i> = 84) |                            |                 | ST131 isolates ( <i>n</i> = 66) |                          |                 |
|--------------------|---------------------------|-------|--------------------------------|-----------------------------|------------------|--|----------------------------|-----------------|---------------------------------|--------------------------|-----------------|
|                    |                           |       | Prevalence, no (column %)      |                             | <i>P</i> -value* | Prevalence, no (column %)                |                            | <i>P</i> -value | Prevalence, no (column %)       |                          | <i>P</i> -value |
|                    |                           |       | ST131 ( <i>n</i> = 66)         | Non-ST131 ( <i>n</i> = 403) |                  | ST131 ( <i>n</i> = 53)                   | Non-ST131 ( <i>n</i> = 31) |                 | H30 ( <i>n</i> = 51)            | Non-H30 ( <i>n</i> = 15) |                 |
| Physician visit    | 1 month                   | 439   | 62 (94)                        | 377 (95)                    | 0.66             | 50 (94)                                  | 29 (94)                    | 0.88            | 48 (94)                         | 14 (100)                 | 0.35            |
|                    | 6 months                  | 406   | 61 (94)                        | 345 (87)                    | 0.11             | 51 (96)                                  | 30 (97)                    | 0.9             | 49 (96)                         | 12 (86)                  | 0.15            |
| Medical lines      | 1 month                   | 209   | 40 (61)                        | 169 (42)                    | <b>0.005</b>     | 32 (60)                                  | 17 (55)                    | 0.62            | 30 (59)                         | 10 (67)                  | 0.59            |
|                    | 6 months                  | 169   | 37 (57)                        | 132 (33)                    | <b>&lt;0.001</b> | 33 (62)                                  | 15 (48)                    | 0.22            | 31 (61)                         | 6 (43)                   | 0.23            |
| Hospital stay      | 1 month                   | 160   | 27 (41)                        | 133 (33)                    | 0.23             | 24 (45)                                  | 13 (42)                    | 0.77            | 23 (45)                         | 4 (27)                   | 0.2             |
|                    | 6 months                  | 112   | 25 (38)                        | 87 (22)                     | <b>0.004</b>     | 22 (42)                                  | 10 (32)                    | 0.4             | 22 (43)                         | 3 (21)                   | 0.14            |
| Nursing home stay  | 1 month                   | 26    | 6 (9)                          | 20 (5)                      | 0.17             | 5 (9)                                    | 4 (13)                     | 0.62            | 5 (10)                          | 1 (7)                    | 0.76            |
|                    | 6 months                  | 29    | 10 (16)                        | 19 (5)                      | <b>0.001</b>     | 10 (19)                                  | 4 (13)                     | 0.46            | 10 (20)                         | 0 (0)                    | 0.07            |
| Surgery            | 1 month                   | 93    | 13 (20)                        | 80 (20)                     | 0.96             | 10 (19)                                  | 4 (13)                     | 0.48            | 9 (18)                          | 4 (27)                   | 0.44            |
|                    | 6 months                  | 90    | 20 (31)                        | 70 (18)                     | <b>0.01</b>      | 16 (30)                                  | 8 (26)                     | 0.67            | 16 (31)                         | 4 (29)                   | 0.84            |
| Antibiotic use     | 1 month                   | 125   | 23 (35)                        | 102 (26)                    | 0.11             | 20 (38)                                  | 14 (47)                    | 0.43            | 19 (37)                         | 4 (27)                   | 0.45            |
|                    | 6 months                  | 154   | 31 (48)                        | 123 (31)                    | <b>0.008</b>     | 29 (55)                                  | 17 (55)                    | 0.99            | 27 (53)                         | 4 (29)                   | 0.11            |
| Acid reducing drug | 1 month                   | 183   | 25 (40)                        | 158 (40)                    | 0.91             | 20 (39)                                  | 17 (57)                    | 0.13            | 19 (39)                         | 6 (43)                   | 0.78            |
| Immunosuppression  | 1 month                   | 11    | 2 (3)                          | 9 (2)                       | 0.68             | 1 (2)                                    | 2 (7)                      | 0.28            | 1 (2)                           | 1 (7)                    | 0.34            |
| Hospital inpatient | Current                   | 79    | 12 (18)                        | 67 (17)                     | 0.71             | 8 (15)                                   | 5 (16)                     | 0.93            | 8 (16)                          | 4 (27)                   | 0.35            |
| Specimen type      | Blood                     | 15    | 2 (3)                          | 13 (3)                      | 0.93             | 2 (4)                                    | 1 (3)                      | 0.9             | 2 (4)                           | 0 (0)                    | 0.44            |
|                    | Urine                     | 366   | 46 (70)                        | 320 (79)                    | 0.08             | 40 (75)                                  | 25 (81)                    | 0.58            | 38 (75)                         | 8 (53)                   | 0.12            |
|                    | Wound                     | 52    | 8 (12)                         | 44 (11)                     | 0.77             | 4 (8)                                    | 1 (3)                      | 0.42            | 4 (8)                           | 4 (27)                   | <b>0.05</b>     |
|                    | Other                     | 36    | 10 (15)                        | 26 (6)                      | <b>0.01</b>      | 7 (13)                                   | 4 (13)                     | 0.97            | 7 (14)                          | 3 (20)                   | 0.55            |

\*For some variables data were missing for 2-3 subjects. Hypothesis testing with small numbers (cell size <5) was conducted using Fisher's exact test, otherwise, the *P*-value for the  $\chi^2$  test is reported. Bold *P*-values reflect statistically significant differences.

**Table 3.** Environmental factors and *Escherichia coli* ST131 carriage, by ciprofloxacin resistance and ST131-H30 sub-group

|                              |     | All Isolates ( <i>n</i> = 469)<br>Prevalence, no<br>(column %) |              | <i>P</i> -value* | Ciprofloxacin-resistant<br>( <i>n</i> = 84) Prevalence, no<br>(column %) |              | <i>P</i> -value | ST131 ( <i>n</i> = 66)<br>Prevalence, no (column<br>%) |              | <i>P</i> -value |
|------------------------------|-----|--|--------------|------------------|--|--------------|-----------------|--|--------------|-----------------|
|                              |     | <i>n</i> (%)   | <i>n</i> (%) |                  | <i>n</i> (%)   | <i>n</i> (%) |                 | <i>n</i> (%)   | <i>n</i> (%) |                 |
| Prepare meals at home        |     |  |              | 0.53             |  |              | 0.36            |  |              | 0.87            |
| Sometimes or less often      | 224 | 34 (52)  | 190 (47)     |                  | 27 (51)  | 19 (61)      |                 | 26 (51)  | 8 (53)       |                 |
| Most days                    | 243 | 32 (48)  | 211 (53)     |                  | 26 (49)  | 12 (39)      |                 | 25 (49)  | 7 (47)       |                 |
| Eat meat                     |     |  |              | <b>0.01</b>      |  |              | 0.36            |  |              | 0.07            |
| Sometimes or less often      | 181 | 35 (53)  | 146 (36)     |                  | 26 (49)  | 12 (39)      |                 | 24 (47)  | 11 (73)      |                 |
| Most days                    | 286 | 31 (47)  | 255 (64)     |                  | 27 (51)  | 19 (61)      |                 | 27 (53)  | 4 (27)       |                 |
| Eat fresh fruit              |     |  |              | 0.65             |  |              | 0.45            |  |              | 0.75            |
| Sometimes or less often      | 203 | 30 (46)  | 173 (43)     |                  | 24 (45)  | 11 (37)      |                 | 23 (45)  | 7 (50)       |                 |
| Most days                    | 263 | 35 (54)  | 228 (57)     |                  | 29 (55)  | 19 (63)      |                 | 28 (55)  | 7 (50)       |                 |
| Eat salad/raw vegetables     |     |  |              | 0.75             |  |              | 0.56            |  |              | 0.16            |
| Sometimes or less often      | 261 | 38 (58)  | 223 (55)     |                  | 29 (55)  | 19 (61)      |                 | 27 (53)  | 11 (73)      |                 |
| Most days                    | 207 | 28 (42)  | 179 (45)     |                  | 24 (45)  | 12 (39)      |                 | 24 (47)  | 4 (27)       |                 |
| Water source                 |     |  |              |                  |  |              |                 |  |              |                 |
| City water                   | 300 | 45 (68)  | 255 (63)     | 0.44             | 36 (68)  | 27 (87)      | <b>0.05</b>     | 34 (67)  | 11 (73)      | 0.63            |
| Bottled Water                | 168 | 24 (36)  | 144 (36)     | 0.92             | 20 (38)  | 15 (48)      | 0.34            | 20 (39)  | 4 (27)       | 0.37            |
| Well water                   | 109 | 14 (21)  | 95 (24)      | 0.67             | 11 (21)  | 4 (13)       | 0.37            | 11 (22)  | 3 (20)       | 0.9             |
| Waste system                 |     |  |              |                  |  |              |                 |  |              |                 |
| City sewer                   | 363 | 53 (80)  | 310 (77)     | 0.54             | 42 (79)  | 29 (94)      | 0.08            | 40 (78)  | 13 (87)      | 0.48            |
| Septic/field                 | 100 | 13 (20)  | 87 (22)      | 0.73             | 11 (21)  | 2 (6)        | 0.08            | 11 (22)  | 2 (13)       | 0.48            |
| Travel                       |     |  |              |                  |  |              |                 |  |              |                 |
| Trips outside state 1 month  | 139 | 15 (23)  | 124 (32)     | 0.19             | 10 (19)  | 8 (27)       | 0.43            | 9 (18)   | 6 (43)       | <b>0.05</b>     |
| Trips outside state 6 months | 183 | 26 (41)  | 157 (40)     | 0.91             | 22 (42)  | 8 (27)       | 0.16            | 22 (44)  | 4 (29)       | 0.3             |
| Trips outside USA 1 month    | 7   | 0 (0)  | 7 (2)        | 0.28             | 0 (0)  | 1 (3)        | 0.19            | 0 (0)  | 0 (0)        | NS              |
| Trips outside USA 6 months   | 19  | 3 (5)  | 16 (4)       | 0.81             | 1 (2)  | 2 (6)        | 0.28            | 1 (2)  | 2 (14)       | 0.11            |
| Companion animal contact     |     |  |              |                  |  |              |                 |  |              |                 |
| Dog                          | 167 | 26 (39)  | 141 (35)     | 0.49             | 20 (38)  | 10 (32)      | 0.61            | 20 (39)  | 6 (40)       | 0.96            |
| Cat                          | 121 | 9 (14)   | 112 (28)     | <b>0.02</b>      | 8 (15)   | 12 (39)      | <b>0.01</b>     | 8 (16)   | 1 (7)        | 0.37            |
| Bird                         | 9   | 1 (2)  | 8 (2)        | 0.8              | 1 (2)  | 1 (3)        | 0.7             | 1 (2)  | 0 (0)        | 1               |
| Any farm animal contact      | 27  | 7 (11)   | 20 (5)       | 0.07             | 6 (11)   | 0 (0)        | <b>0.05</b>     | 6 (12)   | 1 (7)        | 0.57            |

(Continued)

Table 3. (Continued.)

|                            | All isolates (n = 469)<br>Prevalence, no<br>(column %) |          | Ciprofloxacin-resistant<br>(n = 84) Prevalence, no<br>(column %) |          | ST131 (n = 66)<br>Prevalence, no (column<br>%) |          | P-value |
|----------------------------|--|----------|--|----------|--|----------|---------|
|                            | n (%)  | n (%)    | n (%)  | n (%)    | n (%)  | n (%)    |         |
| Poultry contact            | 11<br>3 (5)  | 8 (2)    | 3 (6)  | 0 (0)    | 3 (6)  | 0 (0)    | 0.34    |
| Touch pets or farm animals |  |          |  |          |  |          | 0.71    |
| Sometimes or less often    | 269<br>58 (58)   | 231 (58) | 32 (60)  | 20 (65)  | 30 (59)  | 8 (53)   |         |
| Most days                  | 198<br>42 (42)   | 170 (42) | 21 (40)  | 11 (35)  | 21 (41)  | 7 (47)   |         |
| Touch wild animals         |  |          |  |          |  |          | 0.70    |
| Never or rarely            | 423<br>83 (83)   | 368 (92) | 45 (85)  | 31 (100) | 43 (84)  | 12 (80)  |         |
| Sometimes                  | 44<br>17 (17)  | 33 (8)   | 8 (15)   | 0 (0)    | 8 (16)   | 3 (20)   |         |
| Touch animal feces         |  |          |  |          |  |          | 1.0     |
| Sometimes or less often    | 426<br>98 (98)   | 361 (91) | 52 (98)  | 28 (90)  | 50 (98)  | 15 (100) |         |
| Most days                  | 38<br>2 (2)  | 37 (9)   | 1 (2)  | 3 (10)   | 1 (2)  | 0 (0)    |         |

\*For some variables, data were missing for 2–3 subjects. Hypothesis testing with small numbers (cell size <5) was conducted using Fisher's exact test, otherwise, the  $\chi^2$  test is reported. Bold P-values reflect statistically significant differences.

## Discussion


Here we assessed self-reported demographics, clinical factors and environmental exposures of veterans with an *E. coli* clinical isolate as predictors of ST131 status (both overall and for fluoroquinolone-resistant isolates) and, among subjects with an ST131 isolate, of H30 subclone status. This is one of few studies to examine non-healthcare-associated risk factors for having a clinical isolate from the pandemic ST131 lineage and specifically its H30 subclone.

Our findings support two main conclusions. First, most of the ST131-associated clinical factors represent traditionally recognised risk factors for having an antimicrobial-resistant infection. However, with stratification by fluoroquinolone resistance status, the ST131-specific associations disappeared. This suggests that these healthcare exposures are not specific to ST131, but are generic markers for infection with antimicrobial-resistant *E. coli* generally.

Second, a modestly (albeit statistically significantly) greater proportion of subjects with non-ST131 *E. coli*, as opposed to ST131, reported frequent exposure to certain hypothesised environmental risk factors. Specifically, non-ST131 group members reported more frequent meat consumption, cat ownership, city water usage, recent out-of-state travel and touching animal feces. By contrast, ST131 group members reported more contact with wild animals. This suggests that contact with wild animals, or other variables associated with wild animal exposure, predispose specifically to having ST131, as has been suggested by others [7]. Carriage of the ST131-H30 subclone was associated with wound specimens, while non-H30 carriage was associated with post-month out-of-state travel.

The study has several limitations. First, relatively few subjects reported having several of the candidate risk factors (e.g. travel or farm animal exposure), or had ST131-H30Rx, limiting statistical power for these variables. Second, all subjects were veterans, limiting generalisability and possibly contributing to our not finding the typical associations of ST131 with older age, comorbidities and overall poor health [8–10]. Third, the requirement for survey completion may have selected for an uncharacteristically healthy and functional subset of veterans. Fourth, risk factors for *E. coli* acquisition or carriage may have occurred earlier in life and hence were unmeasured in this study. Additional limitations include the risks of false positives from multiple testing and of misclassification due to poor subject recall.

Specific pandemic lineages clearly contribute disproportionately to extraintestinal *E. coli* infections, especially if antimicrobial-resistant, making their potential reservoirs and modes of transmission important to understand. In this veteran-based study population, ST131 was associated preferentially with healthcare-associated exposures and wild animal contact, whereas non-ST131 *E. coli* were associated with other environmental exposures.

**Author ORCIDs.**  Amee R. Manges [0000-0003-2462-7249](https://orcid.org/0000-0003-2462-7249).

**Acknowledgements.** This work was supported in part by Office of Research and Development, Department of Veterans Affairs (USA), grants 1 I01 CX000920-01A1 and 2 I01CX000920-04 (to J.R.J.). The views represented here are those of the authors and not those of their respective institutions or the Department of Veterans Affairs.

**Conflict of interest.** Dr Johnson has received research funding from Merck, Allergan and Tetrphase, is a consultant for Janssen/Cruell and has patent applications for tests to detect *E. coli* strains. The other authors report no financial conflicts of interest.

## References

1. **Stoesser N *et al.*** (2016) Evolutionary history of the global emergence of the *Escherichia coli* epidemic clone ST131. *mBio* **7**, e02162–15.
2. **Nicolas-Chanoine M-H, Bertrand X and Madec J-Y** (2014) *Escherichia coli* ST131, an intriguing clonal group. *Clinical Microbiology Reviews* **27**, 543–574.
3. **Banerjee R *et al.*** (2013) Molecular epidemiology of *Escherichia coli* sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-beta-lactamase-positive and -negative *E. coli* clinical isolates from the Chicago region, 2007 to 2010. *Antimicrobial Agents and Chemotherapy* **57**, 6385–6388.
4. **Can F *et al.*** (2015) Emerging *Escherichia coli* O25b/ST131 clone predicts treatment failure in urinary tract infections. *Clinical Infectious Diseases* **60**, 523–527.
5. **Clinical and Laboratory Standards Institute** (2013) *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement*. Wayne, PA: Clinical and Laboratory Standards Institute.
6. **Johnson JR *et al.*** (2014) Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within *Escherichia coli* sequence type 131. *Journal of Clinical Microbiology* **52**, 1358–1365.
7. **Müller A, Stephan R and Nüesch-Inderbinen M** (2016) Distribution of virulence factors in ESBL-producing *Escherichia coli* isolated from the environment, livestock, food and humans. *Science of the Total Environment Elsevier B.V.* **541**, 667–672.
8. **Blanco J *et al.*** (2011) National survey of *Escherichia coli* causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b: H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. *Journal of Antimicrobial Chemotherapy* **66**, 2011–2021.
9. **Colpan A *et al.*** (2013) *Escherichia coli* sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. *Clinical Infectious Diseases* **57**, 1256–1265.
10. **Price LB, Johnson JR and Aziz M** (2013) The epidemic of extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* ST131 is driven by a single highly pathogenic subclone, H30-Rx. *mBio* **4**, e00377–13.